Forbes Medi-Tech Announces Pharmavite Contract Renewal

VANCOUVER, BRITISH COLUMBIA, Jun 10 (MARKET WIRE) --
Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) today announced it has
extended its supply and licensing contract with Pharmavite LLC until mid
2010 for the continued sale of Reducol(TM), the branded cholesterol
lowering ingredient in one of Pharmavite's leading line of dietary
supplements, Nature Made(R) CholestOff(TM) and CholestOff(TM)
Complete(TM). The license is exclusive to Pharmavite LLC for distribution
and sales in Food, Drug and Mass Merchandiser outlets.

"Since the initial product launch in 2001, the Nature Made(R)
CholestOff(TM) product line has grown significantly, establishing a
strong position in the U.S. 'heart health' dietary supplement market,"
said Laura Wessman, Senior Vice President, Operations at Forbes.

"We are pleased to maintain this relationship and anticipate that
Pharmavite will continue to build awareness and sales of CholestOff(TM)
products," added Ms. Wessman.

CholestOff(TM) and CholestOff(TM) Complete(TM) are available in 60-count
and 120-count caplet bottles. For more information on CholestOff(TM)
products, visit www.cholestoff.com. For more information on Reducol,
visit www.reducol.com.

About Pharmavite LLC

For more than 30 years, Pharmavite has earned and maintained the trust of
pharmacists, consumers, and retailers by manufacturing high-quality
vitamins, minerals, herbs and other dietary supplements that are safe,
effective and science-based. As an industry leader, Pharmavite adheres to
manufacturing standards recommended by the United States Pharmacopeia
(USP), a not-for-profit organization that has set pharmaceutical and
dietary supplement quality standards since 1820. In addition, Pharmavite
participates in USP's Verification Program for dietary supplements. The
dietary supplement industry is regulated by the U.S. Food and Drug
Administration and the Federal Trade Commission, as well as by government
agencies in each of the 50 states. For more information please visit
www.pharmavite.com.

About Forbes Medi-Tech

Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) is a life sciences company
focused on evidence-based nutritional solutions. A leader in
nutraceutical technology, Forbes is a provider of value-added products
and cholesterol-lowering ingredients for use in functional foods and
dietary supplements. Forbes successfully developed and commercialized its
Reducol(TM) plant sterol blend, which has undergone clinical trials in
various matrices and has been shown to lower "LDL" cholesterol levels
safely and naturally. Building upon established partnerships with leading
retailers and manufacturers across the globe, Forbes helps its customers
to develop private label and branded products.

Nature Made(R) is a registered trademark of Pharmavite LLC.

Pharmavite(TM), CholestOff(TM), and CholestOff(TM) Complete(TM) are
trademarks of Pharmavite LLC.

Forward Looking Statements

Forbes Medi-Tech ("Forbes" or the "Company") has relied solely on
Pharmavite LLC for the information about Pharmavite(TM), Nature Made(R),
CholestOff(TM) and CholestOff(TM) Complete(TM) provided in this News
Release and the Company disclaims any liability with respect to such
information. Forbes disclaims responsibility or liability for information
contained in any linked or referenced website, and such links and
references do not constitute an endorsement by Forbes of such websites.
This News Release contains forward-looking statements and information
about Pharmavite's agreement with the Company, Reducol(TM) and
CholestOff(TM) products, and the Company's expectation that Pharmavite
will continue to build awareness and sales of CholestOff(TM) products.
Forward-looking statements and information can be identified by the use
of forward-looking terminology such as "mid 2010", "maintain",
"anticipate", "extended" or comparable terminology referring to future
events or results. The Company's actual results could differ materially
from those anticipated in these forward-looking statements and
information as a result of numerous factors, including the Company's
reliance on Pharmavite for performance; the Company's need for additional
funding to continue operations; the Company's ability to attract and
retain key personnel; changes in business strategy or plans by either the
Company or Pharmavite; intellectual property risks; exchange rate
fluctuations; and other risks applicable to both the Company and to
Pharmavite including without limitation, industry and government
regulation; manufacturing risks, marketing risks, product liability and
insurance risks, the effect of competition, the effect of global economic
conditions, and the risk of unknown side effects. Such risks and
uncertainties, and others affecting the Company which could cause actual
results to vary materially from current results or those anticipated in
forward-looking statements and information, are more fully described in
the Company's latest Annual Report on Form 20-F, and latest MD&A and
other reports, filed with the Canadian Securities Regulatory Authorities
from time to time at www.sedar.com, and with the U.S. SEC at
www.sec.gov/edgar.shtml. Forward-looking statements and information are
based on the beliefs, assumptions, opinions and expectations of the
Company's management at the time they are made, and the Company does not
assume any obligation to update any forward-looking statement or
information should those beliefs, assumptions, opinions or expectations
change, except as required by law.

Contacts:
Forbes Medi-Tech Inc.
David Goold
Chief Financial Officer
(604) 681-8976 ext. 239
ir@forbesmedi.com
www.forbesmedi.com

Copyright 2009, Market Wire, All rights reserved.

-0-